| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 2.51e-12 | 14 | 64 | 6 | GO:0005130 | |
| GeneOntologyMolecularFunction | Toll-like receptor binding | 3.66e-12 | 29 | 64 | 7 | GO:0035325 | |
| GeneOntologyMolecularFunction | bile acid transmembrane transporter activity | 1.25e-11 | 34 | 64 | 7 | GO:0015125 | |
| GeneOntologyMolecularFunction | organic hydroxy compound transmembrane transporter activity | 5.72e-11 | 70 | 64 | 8 | GO:1901618 | |
| GeneOntologyMolecularFunction | GPI anchor binding | 8.25e-11 | 23 | 64 | 6 | GO:0034235 | |
| GeneOntologyMolecularFunction | filamin binding | 3.82e-10 | 29 | 64 | 6 | GO:0031005 | |
| GeneOntologyMolecularFunction | lipid transmembrane transporter activity | 3.42e-09 | 73 | 64 | 7 | GO:0170055 | |
| GeneOntologyMolecularFunction | glycolipid binding | 1.07e-08 | 49 | 64 | 6 | GO:0051861 | |
| GeneOntologyMolecularFunction | monocarboxylic acid transmembrane transporter activity | 1.50e-08 | 90 | 64 | 7 | GO:0008028 | |
| GeneOntologyMolecularFunction | actin binding | FLNC PSG1 PSG2 PSG3 PSG9 PSG11 SIPA1L1 SPTBN1 KCNMA1 PSG8 PLEC | 3.19e-07 | 479 | 64 | 11 | GO:0003779 |
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 4.87e-07 | 149 | 64 | 7 | GO:1990782 | |
| GeneOntologyMolecularFunction | ankyrin binding | 8.12e-07 | 23 | 64 | 4 | GO:0030506 | |
| GeneOntologyMolecularFunction | lipid transporter activity | 3.05e-06 | 196 | 64 | 7 | GO:0005319 | |
| GeneOntologyMolecularFunction | organic anion transmembrane transporter activity | 4.24e-06 | 293 | 64 | 8 | GO:0008514 | |
| GeneOntologyMolecularFunction | carboxylic acid transmembrane transporter activity | 4.38e-06 | 207 | 64 | 7 | GO:0046943 | |
| GeneOntologyMolecularFunction | organic acid transmembrane transporter activity | 4.52e-06 | 208 | 64 | 7 | GO:0005342 | |
| GeneOntologyMolecularFunction | protein heterodimerization activity | 4.74e-06 | 398 | 64 | 9 | GO:0046982 | |
| GeneOntologyMolecularFunction | phosphatidylinositol binding | 7.38e-06 | 316 | 64 | 8 | GO:0035091 | |
| GeneOntologyMolecularFunction | cytoskeletal protein binding | MAGI1 FLNC PSG1 PSG2 PSG3 PSG9 PSG11 SIPA1L1 SPTBN1 CLTC KCNMA1 PSG8 PLEC EP300 | 7.77e-06 | 1099 | 64 | 14 | GO:0008092 |
| GeneOntologyMolecularFunction | calmodulin binding | 8.73e-06 | 230 | 64 | 7 | GO:0005516 | |
| GeneOntologyMolecularFunction | growth factor receptor binding | 1.92e-05 | 173 | 64 | 6 | GO:0070851 | |
| GeneOntologyMolecularFunction | protein phosphatase binding | 5.68e-05 | 210 | 64 | 6 | GO:0019903 | |
| GeneOntologyMolecularFunction | phospholipid binding | 5.94e-05 | 548 | 64 | 9 | GO:0005543 | |
| GeneOntologyMolecularFunction | cytokine receptor binding | 7.80e-05 | 324 | 64 | 7 | GO:0005126 | |
| GeneOntologyMolecularFunction | protein kinase binding | PSG1 PSG2 PSG3 PSG7 PSG9 PSG11 SIPA1L1 CLTC PSG8 DNAJC3 EP300 | 9.32e-05 | 873 | 64 | 11 | GO:0019901 |
| GeneOntologyMolecularFunction | phosphatase binding | 1.99e-04 | 264 | 64 | 6 | GO:0019902 | |
| GeneOntologyMolecularFunction | clathrin light chain binding | 2.10e-04 | 7 | 64 | 2 | GO:0032051 | |
| GeneOntologyMolecularFunction | kinase binding | PSG1 PSG2 PSG3 PSG7 PSG9 PSG11 SIPA1L1 CLTC PSG8 DNAJC3 EP300 | 2.33e-04 | 969 | 64 | 11 | GO:0019900 |
| GeneOntologyMolecularFunction | transmembrane transporter activity | ABCC3 PSG1 PSG2 PSG3 PSG9 PSG11 SCN7A KCNMA1 PSG8 SLC2A13 ANKH | 1.21e-03 | 1180 | 64 | 11 | GO:0022857 |
| GeneOntologyMolecularFunction | 1-acylglycerol-3-phosphate O-acyltransferase activity | 2.04e-03 | 21 | 64 | 2 | GO:0003841 | |
| GeneOntologyMolecularFunction | transporter activity | ABCC3 PSG1 PSG2 PSG3 PSG9 PSG11 SCN7A KCNMA1 PSG8 SLC2A13 ANKH | 2.44e-03 | 1289 | 64 | 11 | GO:0005215 |
| GeneOntologyMolecularFunction | lysophosphatidic acid acyltransferase activity | 2.67e-03 | 24 | 64 | 2 | GO:0042171 | |
| GeneOntologyMolecularFunction | lysophospholipid acyltransferase activity | 2.67e-03 | 24 | 64 | 2 | GO:0071617 | |
| GeneOntologyMolecularFunction | lipid binding | 4.08e-03 | 988 | 64 | 9 | GO:0008289 | |
| GeneOntologyMolecularFunction | acylglycerol O-acyltransferase activity | 4.71e-03 | 32 | 64 | 2 | GO:0016411 | |
| GeneOntologyMolecularFunction | protein dimerization activity | 4.76e-03 | 1205 | 64 | 10 | GO:0046983 | |
| GeneOntologyMolecularFunction | actin filament binding | 6.07e-03 | 227 | 64 | 4 | GO:0051015 | |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 1.70e-12 | 14 | 62 | 6 | GO:0070348 | |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 2.82e-12 | 15 | 62 | 6 | GO:0070347 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 2.82e-12 | 15 | 62 | 6 | GO:1903387 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 2.82e-12 | 15 | 62 | 6 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 2.82e-12 | 15 | 62 | 6 | GO:0002859 | |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 4.50e-12 | 16 | 62 | 6 | GO:0038016 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 6.94e-12 | 17 | 62 | 6 | GO:0070342 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 6.94e-12 | 17 | 62 | 6 | GO:1901143 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 6.94e-12 | 17 | 62 | 6 | GO:0038158 | |
| GeneOntologyBiologicalProcess | insulin metabolic process | 9.84e-12 | 35 | 62 | 7 | GO:1901142 | |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 1.04e-11 | 18 | 62 | 6 | GO:1903385 | |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 2.16e-11 | 20 | 62 | 6 | GO:2000346 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 3.01e-11 | 21 | 62 | 6 | GO:0070345 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 3.01e-11 | 21 | 62 | 6 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 3.01e-11 | 21 | 62 | 6 | GO:0002838 | |
| GeneOntologyBiologicalProcess | regulation of vascular permeability | 3.83e-11 | 71 | 62 | 8 | GO:0043114 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 4.13e-11 | 22 | 62 | 6 | GO:0030853 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet aggregation | 5.58e-11 | 23 | 62 | 6 | GO:0090331 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 5.58e-11 | 23 | 62 | 6 | GO:0002858 | |
| GeneOntologyBiologicalProcess | positive regulation of vasculogenesis | 7.42e-11 | 24 | 62 | 6 | GO:2001214 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immune response to tumor cell | 7.42e-11 | 24 | 62 | 6 | GO:0002855 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity directed against tumor cell target | 7.42e-11 | 24 | 62 | 6 | GO:0002420 | |
| GeneOntologyBiologicalProcess | bile acid and bile salt transport | 8.95e-11 | 47 | 62 | 7 | GO:0015721 | |
| GeneOntologyBiologicalProcess | common myeloid progenitor cell proliferation | 9.75e-11 | 25 | 62 | 6 | GO:0035726 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immune response to tumor cell | 9.75e-11 | 25 | 62 | 6 | GO:0002423 | |
| GeneOntologyBiologicalProcess | regulation of fat cell proliferation | 1.62e-10 | 27 | 62 | 6 | GO:0070344 | |
| GeneOntologyBiologicalProcess | negative regulation of homotypic cell-cell adhesion | 2.06e-10 | 28 | 62 | 6 | GO:0034111 | |
| GeneOntologyBiologicalProcess | regulation of vasculogenesis | 2.59e-10 | 29 | 62 | 6 | GO:2001212 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet activation | 4.00e-10 | 31 | 62 | 6 | GO:0010544 | |
| GeneOntologyBiologicalProcess | negative regulation of bone resorption | 4.91e-10 | 32 | 62 | 6 | GO:0045779 | |
| GeneOntologyBiologicalProcess | fat cell proliferation | 4.91e-10 | 32 | 62 | 6 | GO:0070341 | |
| GeneOntologyBiologicalProcess | regulation of blood vessel remodeling | 4.91e-10 | 32 | 62 | 6 | GO:0060312 | |
| GeneOntologyBiologicalProcess | regulation of granulocyte differentiation | 5.98e-10 | 33 | 62 | 6 | GO:0030852 | |
| GeneOntologyBiologicalProcess | negative regulation of feeding behavior | 5.98e-10 | 33 | 62 | 6 | GO:2000252 | |
| GeneOntologyBiologicalProcess | negative regulation of vascular permeability | 7.25e-10 | 34 | 62 | 6 | GO:0043116 | |
| GeneOntologyBiologicalProcess | negative regulation of bone remodeling | 7.25e-10 | 34 | 62 | 6 | GO:0046851 | |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 1.47e-09 | 38 | 62 | 6 | GO:2000345 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 1.74e-09 | 39 | 62 | 6 | GO:0045717 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 2.04e-09 | 40 | 62 | 6 | GO:0045953 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 2.38e-09 | 41 | 62 | 6 | GO:0002716 | |
| GeneOntologyBiologicalProcess | regulation of platelet aggregation | 2.77e-09 | 42 | 62 | 6 | GO:0090330 | |
| GeneOntologyBiologicalProcess | negative regulation of behavior | 4.28e-09 | 45 | 62 | 6 | GO:0048521 | |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 4.91e-09 | 46 | 62 | 6 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 4.91e-09 | 46 | 62 | 6 | GO:0072574 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 5.61e-09 | 47 | 62 | 6 | GO:0001911 | |
| GeneOntologyBiologicalProcess | negative regulation of tissue remodeling | 5.61e-09 | 47 | 62 | 6 | GO:0034104 | |
| GeneOntologyBiologicalProcess | vascular process in circulatory system | ABCC3 PSG1 PSG2 PSG3 PSG9 PSG11 KCNMA1 PSG8 TACR1 SLC2A13 PLEC | 5.63e-09 | 344 | 62 | 11 | GO:0003018 |
| GeneOntologyBiologicalProcess | negative regulation of myeloid leukocyte differentiation | 6.43e-09 | 85 | 62 | 7 | GO:0002762 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 7.28e-09 | 49 | 62 | 6 | GO:0072576 | |
| GeneOntologyBiologicalProcess | regulation of immune response to tumor cell | 7.28e-09 | 49 | 62 | 6 | GO:0002837 | |
| GeneOntologyBiologicalProcess | regulation of response to tumor cell | 8.25e-09 | 50 | 62 | 6 | GO:0002834 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 1.05e-08 | 52 | 62 | 6 | GO:0031342 | |
| GeneOntologyBiologicalProcess | regulation of homotypic cell-cell adhesion | 1.18e-08 | 53 | 62 | 6 | GO:0034110 | |
| GeneOntologyBiologicalProcess | immune response to tumor cell | 1.66e-08 | 56 | 62 | 6 | GO:0002418 | |
| GeneOntologyBiologicalProcess | negative regulation of wound healing | 1.75e-08 | 98 | 62 | 7 | GO:0061045 | |
| GeneOntologyBiologicalProcess | negative regulation of protein kinase activity | 1.96e-08 | 221 | 62 | 9 | GO:0006469 | |
| GeneOntologyBiologicalProcess | negative regulation of osteoclast differentiation | 2.29e-08 | 59 | 62 | 6 | GO:0045671 | |
| GeneOntologyBiologicalProcess | granulocyte differentiation | 2.54e-08 | 60 | 62 | 6 | GO:0030851 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid metabolic process | 2.54e-08 | 60 | 62 | 6 | GO:0045922 | |
| GeneOntologyBiologicalProcess | regulation of feeding behavior | 2.81e-08 | 61 | 62 | 6 | GO:0060259 | |
| GeneOntologyBiologicalProcess | negative regulation of kinase activity | 3.46e-08 | 236 | 62 | 9 | GO:0033673 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response | 3.85e-08 | 239 | 62 | 9 | GO:0050777 | |
| GeneOntologyBiologicalProcess | regulation of platelet activation | 4.54e-08 | 66 | 62 | 6 | GO:0010543 | |
| GeneOntologyBiologicalProcess | regulation of endothelial cell differentiation | 4.98e-08 | 67 | 62 | 6 | GO:0045601 | |
| GeneOntologyBiologicalProcess | negative regulation of innate immune response | 5.01e-08 | 114 | 62 | 7 | GO:0045824 | |
| GeneOntologyBiologicalProcess | negative regulation of blood coagulation | 5.95e-08 | 69 | 62 | 6 | GO:0030195 | |
| GeneOntologyBiologicalProcess | regulation of bone resorption | 6.50e-08 | 70 | 62 | 6 | GO:0045124 | |
| GeneOntologyBiologicalProcess | negative regulation of hemostasis | 6.50e-08 | 70 | 62 | 6 | GO:1900047 | |
| GeneOntologyBiologicalProcess | response to tumor cell | 7.08e-08 | 71 | 62 | 6 | GO:0002347 | |
| GeneOntologyBiologicalProcess | negative regulation of coagulation | 7.71e-08 | 72 | 62 | 6 | GO:0050819 | |
| GeneOntologyBiologicalProcess | negative regulation of interleukin-1 production | 7.71e-08 | 72 | 62 | 6 | GO:0032692 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid biosynthetic process | 8.38e-08 | 73 | 62 | 6 | GO:0042304 | |
| GeneOntologyBiologicalProcess | regulation of ketone metabolic process | 9.49e-08 | 189 | 62 | 8 | GO:0010565 | |
| GeneOntologyBiologicalProcess | negative regulation of response to wounding | 9.99e-08 | 126 | 62 | 7 | GO:1903035 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 1.07e-07 | 76 | 62 | 6 | GO:0042269 | |
| GeneOntologyBiologicalProcess | negative regulation of transferase activity | 1.20e-07 | 273 | 62 | 9 | GO:0051348 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 1.45e-07 | 80 | 62 | 6 | GO:0002715 | |
| GeneOntologyBiologicalProcess | regulation of bone remodeling | 1.45e-07 | 80 | 62 | 6 | GO:0046850 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid metabolic process | 1.52e-07 | 134 | 62 | 7 | GO:0019217 | |
| GeneOntologyBiologicalProcess | negative regulation of myeloid cell differentiation | 1.52e-07 | 134 | 62 | 7 | GO:0045638 | |
| GeneOntologyBiologicalProcess | negative regulation of protein phosphorylation | 1.62e-07 | 375 | 62 | 10 | GO:0001933 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 1.81e-07 | 83 | 62 | 6 | GO:0002707 | |
| GeneOntologyBiologicalProcess | regulation of sprouting angiogenesis | 2.09e-07 | 85 | 62 | 6 | GO:1903670 | |
| GeneOntologyBiologicalProcess | circulatory system process | ABCC3 PSG1 PSG2 PSG3 PTPRO PSG9 PSG11 SCN7A KCNMA1 PSG8 TACR1 SLC2A13 PLEC | 2.16e-07 | 733 | 62 | 13 | GO:0003013 |
| GeneOntologyBiologicalProcess | regulation of epidermal growth factor receptor signaling pathway | 2.24e-07 | 86 | 62 | 6 | GO:0042058 | |
| GeneOntologyBiologicalProcess | positive regulation of cell-cell adhesion | 2.28e-07 | 389 | 62 | 10 | GO:0022409 | |
| GeneOntologyBiologicalProcess | blood vessel remodeling | 2.41e-07 | 87 | 62 | 6 | GO:0001974 | |
| GeneOntologyBiologicalProcess | negative regulation of lipid metabolic process | 2.61e-07 | 145 | 62 | 7 | GO:0045833 | |
| GeneOntologyBiologicalProcess | regulation of lymphocyte proliferation | 2.74e-07 | 301 | 62 | 9 | GO:0050670 | |
| GeneOntologyBiologicalProcess | negative regulation of phosphorylation | 3.01e-07 | 401 | 62 | 10 | GO:0042326 | |
| GeneOntologyBiologicalProcess | negative regulation of small molecule metabolic process | 3.14e-07 | 149 | 62 | 7 | GO:0062014 | |
| GeneOntologyBiologicalProcess | negative regulation of lipid biosynthetic process | 3.15e-07 | 91 | 62 | 6 | GO:0051055 | |
| GeneOntologyBiologicalProcess | regulation of blood coagulation | 3.15e-07 | 91 | 62 | 6 | GO:0030193 | |
| GeneOntologyBiologicalProcess | regulation of mononuclear cell proliferation | 3.15e-07 | 306 | 62 | 9 | GO:0032944 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte differentiation | 3.44e-07 | 151 | 62 | 7 | GO:1902106 | |
| GeneOntologyBiologicalProcess | negative regulation of response to biotic stimulus | 3.44e-07 | 151 | 62 | 7 | GO:0002832 | |
| GeneOntologyBiologicalProcess | regulation of ERBB signaling pathway | 3.58e-07 | 93 | 62 | 6 | GO:1901184 | |
| GeneOntologyBiologicalProcess | regulation of hemostasis | 3.58e-07 | 93 | 62 | 6 | GO:1900046 | |
| GeneOntologyBiologicalProcess | platelet aggregation | 4.06e-07 | 95 | 62 | 6 | GO:0070527 | |
| GeneOntologyBiologicalProcess | regulation of lipid metabolic process | 4.13e-07 | 415 | 62 | 10 | GO:0019216 | |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 4.59e-12 | 16 | 63 | 6 | GO:0070021 | |
| GeneOntologyCellularComponent | lateral plasma membrane | 9.84e-09 | 90 | 63 | 7 | GO:0016328 | |
| GeneOntologyCellularComponent | serine/threonine protein kinase complex | 4.58e-07 | 157 | 63 | 7 | GO:1902554 | |
| GeneOntologyCellularComponent | ciliary membrane | 4.98e-07 | 98 | 63 | 6 | GO:0060170 | |
| GeneOntologyCellularComponent | T cell receptor complex | 5.91e-07 | 163 | 63 | 7 | GO:0042101 | |
| GeneOntologyCellularComponent | protein kinase complex | 7.84e-07 | 170 | 63 | 7 | GO:1902911 | |
| GeneOntologyCellularComponent | apical plasma membrane | 1.82e-06 | 487 | 63 | 10 | GO:0016324 | |
| GeneOntologyCellularComponent | adherens junction | 3.42e-06 | 212 | 63 | 7 | GO:0005912 | |
| GeneOntologyCellularComponent | side of membrane | PSG1 PSG2 PSG3 PSG9 PSG11 ALG9 KCNMA1 FCRLB GNA15 PSG8 ZAP70 ALOX15 | 9.99e-06 | 875 | 63 | 12 | GO:0098552 |
| GeneOntologyCellularComponent | apical part of cell | 1.02e-05 | 592 | 63 | 10 | GO:0045177 | |
| GeneOntologyCellularComponent | basal plasma membrane | 1.08e-05 | 354 | 63 | 8 | GO:0009925 | |
| GeneOntologyCellularComponent | basal part of cell | 1.73e-05 | 378 | 63 | 8 | GO:0045178 | |
| GeneOntologyCellularComponent | plasma membrane protein complex | PSG1 PSG2 PSG3 PSG9 PSG11 SCN7A CLTC KCNMA1 GNA15 PSG8 ZAP70 | 2.02e-05 | 785 | 63 | 11 | GO:0098797 |
| GeneOntologyCellularComponent | basolateral plasma membrane | 4.90e-05 | 320 | 63 | 7 | GO:0016323 | |
| GeneOntologyCellularComponent | transferase complex, transferring phosphorus-containing groups | 6.53e-05 | 335 | 63 | 7 | GO:0061695 | |
| GeneOntologyCellularComponent | plasma membrane signaling receptor complex | 8.59e-05 | 350 | 63 | 7 | GO:0098802 | |
| GeneOntologyCellularComponent | anchoring junction | 1.44e-04 | 976 | 63 | 11 | GO:0070161 | |
| GeneOntologyCellularComponent | external side of plasma membrane | 1.60e-04 | 519 | 63 | 8 | GO:0009897 | |
| GeneOntologyCellularComponent | cell projection membrane | 3.09e-04 | 431 | 63 | 7 | GO:0031253 | |
| GeneOntologyCellularComponent | clathrin complex | 3.17e-04 | 9 | 63 | 2 | GO:0071439 | |
| GeneOntologyCellularComponent | cell-cell junction | 3.84e-04 | 591 | 63 | 8 | GO:0005911 | |
| GeneOntologyCellularComponent | cell surface | PSG1 PSG2 PSG3 PSG7 PSG9 PSG11 KCNMA1 FCRLB PSG8 TACR1 ADAM28 | 4.39e-04 | 1111 | 63 | 11 | GO:0009986 |
| GeneOntologyCellularComponent | clathrin coat of trans-Golgi network vesicle | 1.33e-03 | 18 | 63 | 2 | GO:0030130 | |
| GeneOntologyCellularComponent | membrane protein complex | CLTCL1 PSG1 PSG2 PSG3 PSG9 PSG11 SCN7A CLTC KCNMA1 GNA15 PSG8 ZAP70 | 1.53e-03 | 1498 | 63 | 12 | GO:0098796 |
| GeneOntologyCellularComponent | outer membrane | 1.58e-03 | 281 | 63 | 5 | GO:0019867 | |
| GeneOntologyCellularComponent | receptor complex | 1.78e-03 | 581 | 63 | 7 | GO:0043235 | |
| GeneOntologyCellularComponent | trans-Golgi network transport vesicle membrane | 1.99e-03 | 22 | 63 | 2 | GO:0012510 | |
| GeneOntologyCellularComponent | costamere | 1.99e-03 | 22 | 63 | 2 | GO:0043034 | |
| GeneOntologyCellularComponent | sarcolemma | 2.59e-03 | 190 | 63 | 4 | GO:0042383 | |
| GeneOntologyCellularComponent | lysosome | 2.91e-03 | 811 | 63 | 8 | GO:0005764 | |
| GeneOntologyCellularComponent | lytic vacuole | 2.91e-03 | 811 | 63 | 8 | GO:0000323 | |
| GeneOntologyCellularComponent | sarcoplasm | 4.95e-03 | 114 | 63 | 3 | GO:0016528 | |
| GeneOntologyCellularComponent | clathrin vesicle coat | 5.86e-03 | 38 | 63 | 2 | GO:0030125 | |
| GeneOntologyCellularComponent | vacuole | 5.93e-03 | 913 | 63 | 8 | GO:0005773 | |
| GeneOntologyCellularComponent | trans-Golgi network transport vesicle | 6.48e-03 | 40 | 63 | 2 | GO:0030140 | |
| MousePheno | decreased susceptibility to Coronaviridae infection induced morbidity/mortality | 3.75e-11 | 17 | 56 | 6 | MP:0031047 | |
| MousePheno | increased skeletal muscle triglyceride level | 1.63e-10 | 21 | 56 | 6 | MP:0031415 | |
| MousePheno | decreased fatty acid oxidation | 3.99e-10 | 24 | 56 | 6 | MP:0014172 | |
| MousePheno | increased abdominal fat pad weight | 8.70e-10 | 27 | 56 | 6 | MP:0009286 | |
| MousePheno | decreased susceptibility to Coronaviridae infection | 1.10e-09 | 28 | 56 | 6 | MP:0020950 | |
| MousePheno | abnormal skeletal muscle triglyceride level | 2.14e-09 | 31 | 56 | 6 | MP:0031413 | |
| MousePheno | decreased carbon dioxide production | 2.14e-09 | 31 | 56 | 6 | MP:0008964 | |
| MousePheno | decreased skeletal muscle cell glucose uptake | 4.66e-09 | 35 | 56 | 6 | MP:0031618 | |
| MousePheno | abnormal muscle triglyceride level | 5.57e-09 | 36 | 56 | 6 | MP:0031412 | |
| MousePheno | decreased muscle cell glucose uptake | 9.25e-09 | 39 | 56 | 6 | MP:0030022 | |
| MousePheno | decreased susceptibility to Riboviria infection induced morbidity/mortality | 1.97e-08 | 44 | 56 | 6 | MP:0031023 | |
| MousePheno | abnormal skeletal muscle cell glucose uptake | 2.97e-08 | 47 | 56 | 6 | MP:0031617 | |
| MousePheno | abnormal susceptibility to Coronaviridae infection | 3.84e-08 | 49 | 56 | 6 | MP:0020948 | |
| MousePheno | decreased cellular glucose uptake | 6.23e-08 | 53 | 56 | 6 | MP:0003926 | |
| MousePheno | abnormal fatty acid oxidation | 6.99e-08 | 54 | 56 | 6 | MP:0010953 | |
| MousePheno | decreased susceptibility to viral infection induced morbidity/mortality | 1.33e-07 | 60 | 56 | 6 | MP:0009790 | |
| MousePheno | abnormal lipid oxidation | 1.47e-07 | 61 | 56 | 6 | MP:0010951 | |
| MousePheno | increased insulin secretion | 1.97e-07 | 64 | 56 | 6 | MP:0003058 | |
| MousePheno | abnormal muscle cell glucose uptake | 2.60e-07 | 67 | 56 | 6 | MP:0004130 | |
| MousePheno | abnormal carbon dioxide production | 2.60e-07 | 67 | 56 | 6 | MP:0008962 | |
| MousePheno | decreased respiratory quotient | 2.60e-07 | 110 | 56 | 7 | MP:0010379 | |
| MousePheno | abnormal vascular wound healing | 4.35e-07 | 73 | 56 | 6 | MP:0004883 | |
| MousePheno | decreased susceptibility to infection induced morbidity/mortality | 4.72e-07 | 120 | 56 | 7 | MP:0009786 | |
| MousePheno | decreased oxygen consumption | 6.97e-07 | 79 | 56 | 6 | MP:0005290 | |
| MousePheno | polyphagia | 7.51e-07 | 80 | 56 | 6 | MP:0001433 | |
| MousePheno | decreased susceptibility to Riboviria infection | 8.70e-07 | 82 | 56 | 6 | MP:0020914 | |
| MousePheno | decreased circulating triglyceride level | 1.31e-06 | 275 | 56 | 9 | MP:0002644 | |
| MousePheno | abnormal cellular glucose uptake | 3.14e-06 | 102 | 56 | 6 | MP:0003925 | |
| MousePheno | abnormal skeletal muscle morphology | TMEM106B FLNC PSG1 PSG2 PSG3 PSG9 PSG11 LAMA2 PSG8 PLEC EP300 | 4.43e-06 | 508 | 56 | 11 | MP:0000759 |
| MousePheno | increased incidence of induced tumors | 5.48e-06 | 173 | 56 | 7 | MP:0002021 | |
| MousePheno | obese | 5.70e-06 | 113 | 56 | 6 | MP:0001261 | |
| MousePheno | abnormal respiratory quotient | 6.61e-06 | 178 | 56 | 7 | MP:0004129 | |
| MousePheno | decreased energy expenditure | 7.69e-06 | 119 | 56 | 6 | MP:0004890 | |
| MousePheno | decreased triglyceride level | 8.94e-06 | 348 | 56 | 9 | MP:0005318 | |
| MousePheno | increased circulating leptin level | 1.02e-05 | 125 | 56 | 6 | MP:0005669 | |
| MousePheno | decreased susceptibility to viral infection | 1.02e-05 | 125 | 56 | 6 | MP:0002410 | |
| MousePheno | abnormal wound healing | 1.12e-05 | 193 | 56 | 7 | MP:0005023 | |
| MousePheno | increased incidence of tumors by chemical induction | 2.03e-05 | 141 | 56 | 6 | MP:0004499 | |
| MousePheno | abnormal glycogen homeostasis | 2.29e-05 | 144 | 56 | 6 | MP:0005438 | |
| MousePheno | abnormal colon morphology | 3.10e-05 | 152 | 56 | 6 | MP:0000495 | |
| MousePheno | increased tumor incidence | 4.17e-05 | 530 | 56 | 10 | MP:0002020 | |
| MousePheno | absent paranasal sinus | 4.72e-05 | 3 | 56 | 2 | MP:0030382 | |
| MousePheno | abnormal insulin secretion | 6.00e-05 | 171 | 56 | 6 | MP:0003564 | |
| MousePheno | decreased susceptibility to infection | 6.70e-05 | 255 | 56 | 7 | MP:0002409 | |
| MousePheno | abnormal endocrine pancreas secretion | 7.05e-05 | 176 | 56 | 6 | MP:0014195 | |
| MousePheno | abnormal pancreas secretion | 8.75e-05 | 183 | 56 | 6 | MP:0002694 | |
| MousePheno | abnormal endocrine gland physiology | 9.15e-05 | 363 | 56 | 8 | MP:0013561 | |
| MousePheno | abnormal incidence of induced tumors | 9.37e-05 | 269 | 56 | 7 | MP:0013151 | |
| MousePheno | abnormal susceptibility to Riboviria infection | 9.57e-05 | 186 | 56 | 6 | MP:0020912 | |
| MousePheno | increased food intake | 1.04e-04 | 189 | 56 | 6 | MP:0011939 | |
| MousePheno | abnormal food intake | 1.13e-04 | 481 | 56 | 9 | MP:0005449 | |
| MousePheno | abnormal susceptibility to infection induced morbidity/mortality | 1.18e-04 | 279 | 56 | 7 | MP:0009785 | |
| MousePheno | abnormal susceptibility to viral infection | 1.18e-04 | 279 | 56 | 7 | MP:0020185 | |
| MousePheno | abnormal oxygen consumption | 1.24e-04 | 195 | 56 | 6 | MP:0005288 | |
| MousePheno | abnormal pancreatic beta cell physiology | 1.28e-04 | 196 | 56 | 6 | MP:0003562 | |
| MousePheno | increased circulating insulin level | 1.28e-04 | 283 | 56 | 7 | MP:0002079 | |
| MousePheno | insulin resistance | 1.31e-04 | 197 | 56 | 6 | MP:0005331 | |
| MousePheno | abnormal endocrine pancreas physiology | 1.50e-04 | 202 | 56 | 6 | MP:0010147 | |
| MousePheno | abnormal paranasal sinus morphology | 1.56e-04 | 5 | 56 | 2 | MP:0002240 | |
| MousePheno | abnormal blood vessel physiology | 1.61e-04 | 394 | 56 | 8 | MP:0000249 | |
| MousePheno | abnormal tumor incidence | 1.87e-04 | 635 | 56 | 10 | MP:0002019 | |
| MousePheno | abnormal circulating triglyceride level | 1.91e-04 | 516 | 56 | 9 | MP:0011969 | |
| MousePheno | abnormal vasculature physiology | 1.91e-04 | 404 | 56 | 8 | MP:0031170 | |
| MousePheno | abnormal tumor susceptibility | 2.26e-04 | 650 | 56 | 10 | MP:0002166 | |
| MousePheno | abnormal joint physiology | 2.80e-04 | 145 | 56 | 5 | MP:0031169 | |
| MousePheno | abnormal muscle physiology | SH3TC1 PSG1 PSG2 PSG3 PSG9 PSG11 SPTBN1 KCNMA1 LAMA2 PSG8 PLEC EP300 | 3.23e-04 | 954 | 56 | 12 | MP:0002106 |
| MousePheno | abnormal muscle morphology | TMEM106B FLNC PSG1 PSG2 PSG3 PSG9 PSG11 SPTBN1 LAMA2 PSG8 PLEC ANKH EP300 | 3.38e-04 | 1106 | 56 | 13 | MP:0002108 |
| MousePheno | abnormal circulating leptin level | 3.48e-04 | 236 | 56 | 6 | MP:0005667 | |
| MousePheno | increased lean body mass | 5.02e-04 | 354 | 56 | 7 | MP:0003960 | |
| MousePheno | increased triglyceride level | 5.02e-04 | 354 | 56 | 7 | MP:0005317 | |
| MousePheno | decreased lipid level | 5.50e-04 | 727 | 56 | 10 | MP:0014461 | |
| MousePheno | abnormal gas homeostasis | 5.80e-04 | 600 | 56 | 9 | MP:0003948 | |
| MousePheno | abnormal abdominal fat pad morphology | 6.06e-04 | 262 | 56 | 6 | MP:0000010 | |
| MousePheno | impaired glucose tolerance | 6.08e-04 | 480 | 56 | 8 | MP:0005293 | |
| MousePheno | abnormal eating behavior | 6.08e-04 | 604 | 56 | 9 | MP:0001431 | |
| MousePheno | neoplasm | 6.80e-04 | 747 | 56 | 10 | MP:0002006 | |
| MousePheno | abnormal eye blink conditioning behavior | 6.95e-04 | 10 | 56 | 2 | MP:0002807 | |
| MousePheno | abnormal large intestine morphology | 7.96e-04 | 276 | 56 | 6 | MP:0000489 | |
| MousePheno | abnormal triglyceride level | 9.09e-04 | 639 | 56 | 9 | MP:0000187 | |
| MousePheno | increased physiological sensitivity to xenobiotic | 9.57e-04 | 286 | 56 | 6 | MP:0008873 | |
| MousePheno | abnormal pancreas physiology | 1.07e-03 | 292 | 56 | 6 | MP:0002693 | |
| MousePheno | increased body size | 1.17e-03 | 409 | 56 | 7 | MP:0001264 | |
| MousePheno | abnormal susceptibility to infection | 1.30e-03 | 672 | 56 | 9 | MP:0001793 | |
| MousePheno | muscle degeneration | 1.38e-03 | 55 | 56 | 3 | MP:0000749 | |
| MousePheno | abnormal intestine morphology | 1.40e-03 | 546 | 56 | 8 | MP:0000477 | |
| MousePheno | increased total body fat amount | 1.45e-03 | 424 | 56 | 7 | MP:0010024 | |
| MousePheno | increased memory T cell number | 1.52e-03 | 124 | 56 | 4 | MP:0008049 | |
| MousePheno | abnormal energy expenditure | 1.52e-03 | 313 | 56 | 6 | MP:0005450 | |
| MousePheno | abnormal fat pad morphology | 1.55e-03 | 314 | 56 | 6 | MP:0005334 | |
| MousePheno | abnormal consumption behavior | 1.64e-03 | 695 | 56 | 9 | MP:0002069 | |
| MousePheno | abnormal energy homeostasis | 1.76e-03 | 322 | 56 | 6 | MP:0005448 | |
| MousePheno | abnormal nerve fiber response | 1.82e-03 | 16 | 56 | 2 | MP:0003477 | |
| MousePheno | joint inflammation | 1.86e-03 | 131 | 56 | 4 | MP:0002933 | |
| MousePheno | increased autoantibody level | 1.96e-03 | 133 | 56 | 4 | MP:0003725 | |
| MousePheno | abnormal response to infection | 1.97e-03 | 714 | 56 | 9 | MP:0005025 | |
| MousePheno | increased circulating hormone level | 2.01e-03 | 578 | 56 | 8 | MP:0014456 | |
| MousePheno | abnormal joint mobility | 2.06e-03 | 17 | 56 | 2 | MP:0008069 | |
| MousePheno | skeletal muscle fiber necrosis | 2.06e-03 | 17 | 56 | 2 | MP:0009414 | |
| MousePheno | abnormal response to antigen | 2.21e-03 | 726 | 56 | 9 | MP:0020000 | |
| MousePheno | abnormal skeletal muscle fiber size | 2.36e-03 | 140 | 56 | 4 | MP:0009398 | |
| Domain | Ig_2 | 1.55e-10 | 73 | 65 | 8 | PF13895 | |
| Domain | V-set | 3.45e-06 | 184 | 65 | 7 | PF07686 | |
| Domain | ig | 4.27e-06 | 190 | 65 | 7 | PF00047 | |
| Domain | Immunoglobulin | 4.27e-06 | 190 | 65 | 7 | IPR013151 | |
| Domain | Ig_V-set | 5.79e-06 | 199 | 65 | 7 | IPR013106 | |
| Domain | - | 7.50e-06 | 207 | 65 | 7 | 1.25.40.10 | |
| Domain | Clathrin_H-chain_propeller_rpt | 1.19e-05 | 2 | 65 | 2 | IPR022365 | |
| Domain | BID_2 | 1.19e-05 | 2 | 65 | 2 | SM00635 | |
| Domain | Clathrin-link | 1.19e-05 | 2 | 65 | 2 | PF09268 | |
| Domain | - | 1.19e-05 | 2 | 65 | 2 | 2.130.10.110 | |
| Domain | Clathrin_H-chain_link/propller | 1.19e-05 | 2 | 65 | 2 | IPR016025 | |
| Domain | Clathrin_propel | 1.19e-05 | 2 | 65 | 2 | PF01394 | |
| Domain | Big_2 | 1.19e-05 | 2 | 65 | 2 | PF02368 | |
| Domain | Invasin/intimin_cell_adhesion | 1.19e-05 | 2 | 65 | 2 | IPR008964 | |
| Domain | Clathrin_heavy_chain | 1.19e-05 | 2 | 65 | 2 | IPR016341 | |
| Domain | Clathrin_H-chain_linker_core | 1.19e-05 | 2 | 65 | 2 | IPR015348 | |
| Domain | Big_2 | 1.19e-05 | 2 | 65 | 2 | IPR003343 | |
| Domain | Clathrin_H-chain_propeller_N | 1.19e-05 | 2 | 65 | 2 | IPR001473 | |
| Domain | TPR-like_helical_dom | 1.62e-05 | 233 | 65 | 7 | IPR011990 | |
| Domain | - | 1.62e-05 | 663 | 65 | 11 | 2.60.40.10 | |
| Domain | IGc2 | 1.71e-05 | 235 | 65 | 7 | SM00408 | |
| Domain | Ig_sub2 | 1.71e-05 | 235 | 65 | 7 | IPR003598 | |
| Domain | Ig-like_fold | 2.90e-05 | 706 | 65 | 11 | IPR013783 | |
| Domain | Clathrin_H-chain_linker | 3.57e-05 | 3 | 65 | 2 | IPR012331 | |
| Domain | SSDP_DNA-bd | 3.57e-05 | 3 | 65 | 2 | IPR008116 | |
| Domain | CLH | 3.57e-05 | 3 | 65 | 2 | SM00299 | |
| Domain | Actinin_actin-bd_CS | 6.78e-05 | 23 | 65 | 3 | IPR001589 | |
| Domain | ACTININ_2 | 6.78e-05 | 23 | 65 | 3 | PS00020 | |
| Domain | ACTININ_1 | 6.78e-05 | 23 | 65 | 3 | PS00019 | |
| Domain | IG | 1.02e-04 | 421 | 65 | 8 | SM00409 | |
| Domain | Ig_sub | 1.02e-04 | 421 | 65 | 8 | IPR003599 | |
| Domain | Clathrin | 2.48e-04 | 7 | 65 | 2 | PF00637 | |
| Domain | CHCR | 2.48e-04 | 7 | 65 | 2 | PS50236 | |
| Domain | TPR_REGION | 2.73e-04 | 165 | 65 | 5 | PS50293 | |
| Domain | TPR | 2.73e-04 | 165 | 65 | 5 | PS50005 | |
| Domain | IG_LIKE | 2.92e-04 | 491 | 65 | 8 | PS50835 | |
| Domain | Clathrin_H-chain/VPS_repeat | 3.29e-04 | 8 | 65 | 2 | IPR000547 | |
| Domain | Ig-like_dom | 3.43e-04 | 503 | 65 | 8 | IPR007110 | |
| Domain | Histone | 9.78e-04 | 56 | 65 | 3 | PF00125 | |
| Domain | Histone_H2A/H2B/H3 | 9.78e-04 | 56 | 65 | 3 | IPR007125 | |
| Domain | TPR_repeat | 1.19e-03 | 133 | 65 | 4 | IPR019734 | |
| Domain | CH | 1.51e-03 | 65 | 65 | 3 | SM00033 | |
| Domain | TPR-contain_dom | 1.85e-03 | 150 | 65 | 4 | IPR013026 | |
| Domain | CH | 1.86e-03 | 70 | 65 | 3 | PF00307 | |
| Domain | - | 1.94e-03 | 71 | 65 | 3 | 1.10.418.10 | |
| Domain | CH | 2.10e-03 | 73 | 65 | 3 | PS50021 | |
| Domain | CH-domain | 2.27e-03 | 75 | 65 | 3 | IPR001715 | |
| Domain | H2B | 2.40e-03 | 21 | 65 | 2 | SM00427 | |
| Domain | HISTONE_H2B | 2.40e-03 | 21 | 65 | 2 | PS00357 | |
| Domain | Histone_H2B | 2.40e-03 | 21 | 65 | 2 | IPR000558 | |
| Domain | Histone-fold | 3.03e-03 | 83 | 65 | 3 | IPR009072 | |
| Domain | WGR_domain | 3.13e-03 | 24 | 65 | 2 | IPR008893 | |
| Domain | LisH | 4.25e-03 | 28 | 65 | 2 | SM00667 | |
| Domain | LisH | 4.25e-03 | 28 | 65 | 2 | IPR006594 | |
| Domain | LISH | 4.25e-03 | 28 | 65 | 2 | PS50896 | |
| Domain | Spectrin_repeat | 4.56e-03 | 29 | 65 | 2 | IPR002017 | |
| Domain | Spectrin/alpha-actinin | 5.53e-03 | 32 | 65 | 2 | IPR018159 | |
| Domain | SPEC | 5.53e-03 | 32 | 65 | 2 | SM00150 | |
| Pathway | REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS | 4.59e-08 | 99 | 49 | 7 | MM14624 | |
| Pathway | WP_EGFR1_SIGNALING_PATHWAY | 2.44e-07 | 188 | 49 | 8 | MM15828 | |
| Pathway | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | 4.42e-06 | 194 | 49 | 7 | M16312 | |
| Pathway | REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL | 1.69e-05 | 158 | 49 | 6 | MM14812 | |
| Pathway | REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION | 2.83e-05 | 258 | 49 | 7 | MM14572 | |
| Pathway | REACTOME_NFE2L2_REGULATING_MDR_ASSOCIATED_ENZYMES | 3.27e-04 | 8 | 49 | 2 | M48022 | |
| Pathway | REACTOME_NEUTROPHIL_DEGRANULATION | 3.43e-04 | 511 | 49 | 8 | MM15330 | |
| Pubmed | Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. | 5.71e-14 | 13 | 65 | 6 | 34058224 | |
| Pubmed | A mouse carcinoembryonic antigen gene family member is a calcium-dependent cell adhesion molecule. | 5.71e-14 | 13 | 65 | 6 | 1985902 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 10964771 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 32169849 | ||
| Pubmed | CEACAM1+ myeloid cells control angiogenesis in inflammation. | 5.71e-14 | 13 | 65 | 6 | 19273835 | |
| Pubmed | Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. | 5.71e-14 | 13 | 65 | 6 | 16638824 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 20044046 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 32150576 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 22469976 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 6265583 | ||
| Pubmed | CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. | 5.71e-14 | 13 | 65 | 6 | 21532628 | |
| Pubmed | Structural and Molecular Evidence Suggesting Coronavirus-driven Evolution of Mouse Receptor. | 5.71e-14 | 13 | 65 | 6 | 28035001 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 34440862 | ||
| Pubmed | CEACAM1 is a potent regulator of B cell receptor complex-induced activation. | 5.71e-14 | 13 | 65 | 6 | 12832451 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 25406283 | ||
| Pubmed | Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. | 5.71e-14 | 13 | 65 | 6 | 15316023 | |
| Pubmed | Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. | 5.71e-14 | 13 | 65 | 6 | 21670291 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 22162753 | ||
| Pubmed | In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. | 5.71e-14 | 13 | 65 | 6 | 23935487 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 2702644 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 8380065 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 1279194 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 15331748 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 22673933 | ||
| Pubmed | Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. | 5.71e-14 | 13 | 65 | 6 | 22406619 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 7628460 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 25724769 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 26374765 | ||
| Pubmed | Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance. | 5.71e-14 | 13 | 65 | 6 | 25972571 | |
| Pubmed | CEACAM1 deficiency delays important wound healing processes. | 5.71e-14 | 13 | 65 | 6 | 22092845 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 11801635 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 28913658 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 19008452 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 18544705 | ||
| Pubmed | Expression of the mouse hepatitis virus receptor by central nervous system microglia. | 5.71e-14 | 13 | 65 | 6 | 15220458 | |
| Pubmed | Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. | 5.71e-14 | 13 | 65 | 6 | 8500759 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 18843289 | ||
| Pubmed | Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. | 5.71e-14 | 13 | 65 | 6 | 9343248 | |
| Pubmed | Ceacam1 deletion causes vascular alterations in large vessels. | 5.71e-14 | 13 | 65 | 6 | 23800882 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 15207636 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 19285068 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 21760897 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 1719235 | ||
| Pubmed | Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. | 5.71e-14 | 13 | 65 | 6 | 1326665 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 21081647 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 11133662 | ||
| Pubmed | Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. | 5.71e-14 | 13 | 65 | 6 | 39168268 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 11483763 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 8402684 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 2164599 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 16619040 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 29377208 | ||
| Pubmed | Expression of MHV-A59 receptor glycoproteins in susceptible and resistant strains of mice. | 5.71e-14 | 13 | 65 | 6 | 8209741 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 27002145 | ||
| Pubmed | Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. | 5.71e-14 | 13 | 65 | 6 | 21949477 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 29396368 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 26219866 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 18003729 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 26284027 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 2133556 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 32521208 | ||
| Pubmed | CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. | 5.71e-14 | 13 | 65 | 6 | 33352461 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 19406938 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 38381498 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 20739537 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 19621080 | ||
| Pubmed | CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. | 5.71e-14 | 13 | 65 | 6 | 29967450 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 1633107 | ||
| Pubmed | Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. | 5.71e-14 | 13 | 65 | 6 | 19358828 | |
| Pubmed | The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis. | 5.71e-14 | 13 | 65 | 6 | 27695943 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 20404914 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 16680193 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 26911181 | ||
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 1653760 | ||
| Pubmed | Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. | 5.71e-14 | 13 | 65 | 6 | 32027621 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 30664851 | ||
| Pubmed | Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. | 5.71e-14 | 13 | 65 | 6 | 27777319 | |
| Pubmed | 5.71e-14 | 13 | 65 | 6 | 18848945 | ||
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 37531413 | ||
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 23780386 | ||
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 28567513 | ||
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 8207827 | ||
| Pubmed | Human CEACAM1-LF regulates lipid storage in HepG2 cells via fatty acid transporter CD36. | 9.98e-14 | 14 | 65 | 6 | 34666041 | |
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 19700760 | ||
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 34619794 | ||
| Pubmed | Expression patterns of CD66a and CD117 in the mouse submandibular gland. | 9.98e-14 | 14 | 65 | 6 | 25498293 | |
| Pubmed | Endothelial barrier function is differentially regulated by CEACAM1-mediated signaling. | 9.98e-14 | 14 | 65 | 6 | 29746166 | |
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 9212243 | ||
| Pubmed | CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo. | 9.98e-14 | 14 | 65 | 6 | 27572314 | |
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 1648219 | ||
| Pubmed | SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. | 9.98e-14 | 14 | 65 | 6 | 17081782 | |
| Pubmed | Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice. | 9.98e-14 | 14 | 65 | 6 | 32209360 | |
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 11994468 | ||
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 11850617 | ||
| Pubmed | CEACAM2 positively regulates integrin αIIbβ3-mediated platelet functions. | 9.98e-14 | 14 | 65 | 6 | 27161904 | |
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 20381490 | ||
| Pubmed | CEACAM1 regulates integrin αIIbβ3-mediated functions in platelets. | 9.98e-14 | 14 | 65 | 6 | 26196244 | |
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 8896983 | ||
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 22962327 | ||
| Pubmed | 9.98e-14 | 14 | 65 | 6 | 17623671 | ||
| Interaction | PSG4 interactions | 6.83e-09 | 8 | 65 | 4 | int:PSG4 | |
| Interaction | TCTN1 interactions | 9.19e-06 | 151 | 65 | 6 | int:TCTN1 | |
| Interaction | CERS2 interactions | 1.53e-05 | 249 | 65 | 7 | int:CERS2 | |
| Interaction | ITGB3 interactions | 1.80e-05 | 170 | 65 | 6 | int:ITGB3 | |
| Interaction | DSCAM interactions | 1.87e-05 | 171 | 65 | 6 | int:DSCAM | |
| Interaction | DNAJC10 interactions | 2.02e-05 | 260 | 65 | 7 | int:DNAJC10 | |
| Interaction | DNAJB12 interactions | 2.06e-05 | 174 | 65 | 6 | int:DNAJB12 | |
| Interaction | PSG1 interactions | 2.20e-05 | 51 | 65 | 4 | int:PSG1 | |
| Interaction | PSG3 interactions | 4.72e-05 | 22 | 65 | 3 | int:PSG3 | |
| Interaction | PSG9 interactions | 4.72e-05 | 22 | 65 | 3 | int:PSG9 | |
| Interaction | DNAJC3 interactions | 8.85e-05 | 226 | 65 | 6 | int:DNAJC3 | |
| Interaction | PYGO1 interactions | 9.90e-05 | 28 | 65 | 3 | int:PYGO1 | |
| Interaction | TRDN interactions | 1.01e-04 | 75 | 65 | 4 | int:TRDN | |
| Interaction | NUP210L interactions | 1.02e-04 | 5 | 65 | 2 | int:NUP210L | |
| Interaction | CALU interactions | 1.02e-04 | 336 | 65 | 7 | int:CALU | |
| Interaction | CTSB interactions | 1.29e-04 | 242 | 65 | 6 | int:CTSB | |
| Interaction | TFRC interactions | 1.70e-04 | 489 | 65 | 8 | int:TFRC | |
| Interaction | EDC3 interactions | 1.72e-04 | 161 | 65 | 5 | int:EDC3 | |
| Interaction | BCL9 interactions | 1.72e-04 | 86 | 65 | 4 | int:BCL9 | |
| Interaction | EPHA10 interactions | 1.72e-04 | 86 | 65 | 4 | int:EPHA10 | |
| Interaction | DDOST interactions | 2.01e-04 | 375 | 65 | 7 | int:DDOST | |
| Cytoband | 19q13.2 | 3.82e-09 | 164 | 65 | 7 | 19q13.2 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr19q13 | 4.51e-05 | 1192 | 65 | 9 | chr19q13 | |
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 7.07e-17 | 11 | 42 | 7 | 1315 | |
| GeneFamily | Adenosine receptors|V-set domain containing | 1.96e-06 | 163 | 42 | 6 | 590 | |
| GeneFamily | Tetratricopeptide repeat domain containing|Bardet-Biedl syndrome associated|BBSome | 1.44e-04 | 115 | 42 | 4 | 769 | |
| Coexpression | DESCARTES_FETAL_PLACENTA_TROPHOBLAST_GIANT_CELLS | 6.10e-11 | 93 | 63 | 8 | M40279 | |
| Coexpression | GIBBONS_GENETIC_MOUSE_MODEL_LUNG_ADENOCARCINOMA_DOWN_IN_METASTASIS | 1.30e-10 | 32 | 63 | 6 | MM2 | |
| Coexpression | OUYANG_PROSTATE_CANCER_MARKERS | 2.32e-10 | 35 | 63 | 6 | MM757 | |
| Coexpression | WANG_RESPONSE_TO_BEXAROTENE_UP | 1.71e-09 | 48 | 63 | 6 | MM531 | |
| Coexpression | BYSTROEM_CORRELATED_WITH_IL5_DN | 2.67e-08 | 75 | 63 | 6 | MM605 | |
| Coexpression | BROWN_MYELOID_CELL_DEVELOPMENT_UP | 2.81e-08 | 201 | 63 | 8 | MM1006 | |
| Coexpression | HOLLERN_EMT_BREAST_TUMOR_DN | 3.58e-08 | 135 | 63 | 7 | MM965 | |
| Coexpression | BOYLAN_MULTIPLE_MYELOMA_PCA3_DN | 6.55e-08 | 87 | 63 | 6 | MM851 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_3_4WK_UP | 7.96e-08 | 230 | 63 | 8 | MM986 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP | 6.52e-07 | 128 | 63 | 6 | MM1000 | |
| Coexpression | MARTINEZ_TP53_TARGETS_UP | TMEM106B AGPAT5 PSG1 PSG2 PSG3 PSG9 PSG11 SPTBN1 LAMA2 PSG8 BCL2L13 | 7.30e-07 | 694 | 63 | 11 | MM1039 |
| Coexpression | LIM_MAMMARY_STEM_CELL_DN | 9.60e-07 | 436 | 63 | 9 | MM1326 | |
| Coexpression | DESCARTES_FETAL_ADRENAL_CSH1_CSH2_POSITIVE_CELLS | 1.12e-06 | 224 | 63 | 7 | M40145 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_5_6WK_UP | 1.25e-06 | 143 | 63 | 6 | MM989 | |
| Coexpression | MARTINEZ_RB1_TARGETS_UP | TMEM106B PSG1 PSG2 PSG3 PSG9 PSG11 SPTBN1 PSG8 PLEC BCL2L13 DNAJC3 | 1.38e-06 | 741 | 63 | 11 | MM1037 |
| Coexpression | KUMAR_TARGETS_OF_MLL_AF9_FUSION | 1.58e-06 | 463 | 63 | 9 | MM1011 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_DN | 2.31e-06 | 159 | 63 | 6 | MM760 | |
| Coexpression | MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP | 5.05e-06 | 182 | 63 | 6 | MM993 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_4_5WK_UP | 5.36e-06 | 284 | 63 | 7 | MM987 | |
| Coexpression | MARTINEZ_RB1_AND_TP53_TARGETS_UP | TMEM106B AGPAT5 PSG1 PSG2 PSG3 PSG9 PSG11 SPTBN1 PSG8 BCL2L13 | 5.37e-06 | 689 | 63 | 10 | MM1041 |
| Coexpression | CUI_TCF21_TARGETS_2_DN | TMEM106B PTPRO SCN7A SSBP2 PARP14 LYSMD3 MMD PGM2 EP300 TECPR1 SOS2 | 5.40e-06 | 854 | 63 | 11 | M1533 |
| Coexpression | CUI_TCF21_TARGETS_2_DN | TMEM106B PTPRO SCN7A SSBP2 PARP14 LYSMD3 MMD PGM2 EP300 TECPR1 SOS2 | 7.81e-06 | 888 | 63 | 11 | MM1018 |
| Coexpression | GSE27786_ERYTHROBLAST_VS_MONO_MAC_DN | 8.66e-06 | 200 | 63 | 6 | M4878 | |
| Coexpression | OHGUCHI_LIVER_HNF4A_TARGETS_DN | 8.91e-06 | 201 | 63 | 6 | MM1294 | |
| Coexpression | TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_MYELOID_CELL_AGEING | 1.45e-05 | 219 | 63 | 6 | MM3826 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP | 2.22e-05 | 490 | 63 | 8 | MM1001 | |
| Coexpression | MITSIADES_RESPONSE_TO_APLIDIN_DN | 3.06e-05 | 250 | 63 | 6 | M11318 | |
| Coexpression | DESCARTES_MAIN_FETAL_TROPHOBLAST_GIANT_CELLS | 5.77e-05 | 171 | 63 | 5 | M40134 | |
| Coexpression | NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN | 5.78e-05 | 909 | 63 | 10 | M41018 | |
| Coexpression | TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_EPITHELIAL_CELL_AGEING | 6.29e-05 | 568 | 63 | 8 | MM3824 | |
| Coexpression | ZHANG_UTERUS_C1_REGENERATIVE_UP | 8.71e-05 | 302 | 63 | 6 | MM16604 | |
| Coexpression | PRC2_SUZ12_UP.V1_DN | 9.97e-05 | 192 | 63 | 5 | M2740 | |
| Coexpression | GSE22886_NAIVE_CD4_TCELL_VS_MEMORY_TCELL_UP | 1.05e-04 | 194 | 63 | 5 | M4411 | |
| Coexpression | KOBAYASHI_EGFR_SIGNALING_24HR_UP | 1.08e-04 | 102 | 63 | 4 | M10290 | |
| Coexpression | GSE2826_WT_VS_BTK_KO_BCELL_DN | 1.21e-04 | 200 | 63 | 5 | M4899 | |
| Coexpression | GSE17721_CTRL_VS_GARDIQUIMOD_6H_BMDC_UP | 1.21e-04 | 200 | 63 | 5 | M3785 | |
| Coexpression | GSE17721_0.5H_VS_24H_CPG_BMDC_DN | 1.21e-04 | 200 | 63 | 5 | M4129 | |
| Coexpression | TABULA_MURIS_SENIS_GONADAL_ADIPOSE_TISSUE_ENDOTHELIAL_CELL_AGEING | 2.52e-04 | 1088 | 63 | 10 | MM3699 | |
| Coexpression | BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A | 2.84e-04 | 899 | 63 | 9 | M2242 | |
| Coexpression | SWEET_LUNG_CANCER_KRAS_UP | 2.89e-04 | 534 | 63 | 7 | MM1050 | |
| Coexpression | MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_22 | 3.08e-04 | 11 | 63 | 2 | M11594 | |
| Coexpression | BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A | 3.64e-04 | 930 | 63 | 9 | MM893 | |
| Coexpression | DESCARTES_FETAL_SPLEEN_VASCULAR_ENDOTHELIAL_CELLS | 4.11e-04 | 60 | 63 | 3 | M40290 | |
| Coexpression | ZWANG_EGF_PERSISTENTLY_DN | 4.52e-04 | 62 | 63 | 3 | M2621 | |
| CoexpressionAtlas | placenta | 9.76e-06 | 349 | 64 | 8 | placenta | |
| ToppCell | TCGA-Cervix-Primary_Tumor-Cervical_Carcinoma-Keratinizing_Cervical_Squamous_Cell_Carcinoma-6|TCGA-Cervix / Sample_Type by Project: Shred V9 | 4.87e-08 | 136 | 65 | 6 | 2c723777fadc5946df67d3e992471d8134b827f4 | |
| ToppCell | droplet-Heart-HEART_(ALL_4:4:4:1:1)-30m-Endothelial-endothelial_cell_of_coronary_artery|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.39e-06 | 131 | 65 | 5 | 419a0a83b38eaea890d065c3f252ef83c2d37b5b | |
| ToppCell | 5'-Adult-LargeIntestine-Hematopoietic-Myeloid-cDC1|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.44e-06 | 173 | 65 | 5 | d13ae4046a25ee0fb492ddedf44583a879a432e9 | |
| ToppCell | facs-Thymus|facs / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.33e-06 | 184 | 65 | 5 | 58beef66bbbde2479ec69dfef392d5941cedf230 | |
| ToppCell | facs-Lung-nan-3m-Endothelial-Capillary_Aerocyte_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.35e-06 | 189 | 65 | 5 | 09dd2b3d89416192e84abe302a6237b8f3fdcb6e | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 8.57e-06 | 190 | 65 | 5 | 91ba66d4b56c59523485b17738e93f14bb00afa4 | |
| ToppCell | Children_(3_yrs)-Immune-interstitial_macrophage_(C1Q_positive)-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 8.57e-06 | 190 | 65 | 5 | 2d54fca50593fbd11fe13fc2bfaf937a05db776d | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 8.57e-06 | 190 | 65 | 5 | 0724665ac8238f2383c3a929d89abf4a48ec2420 | |
| ToppCell | RV-01._Fibroblast_I|World / Chamber and Cluster_Paper | 8.79e-06 | 191 | 65 | 5 | 70c067c54084bfb02c29bab085f4defd477194fb | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.01e-06 | 192 | 65 | 5 | 446c61c0d6ba89c619efe87ee495951299953981 | |
| ToppCell | RV-01._Fibroblast_I|RV / Chamber and Cluster_Paper | 9.01e-06 | 192 | 65 | 5 | 356160b113c3305a61ceeaff33ce3c9da0be2878 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.24e-06 | 193 | 65 | 5 | ac227ddabfb3f021b1b39dba73f898517cd5a58e | |
| ToppCell | LV-01._Fibroblast_I|LV / Chamber and Cluster_Paper | 9.24e-06 | 193 | 65 | 5 | dc17f3b9758936d428cf17f77a1ce6d4c479b165 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-B_cell|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.24e-06 | 193 | 65 | 5 | f4135615ee0118eec9e221becdd67888e0c2a112 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.48e-06 | 194 | 65 | 5 | 5cd72330c9d9bb21b6c9d5d35085eade101486d1 | |
| ToppCell | RV-02._Fibroblast_II|RV / Chamber and Cluster_Paper | 9.48e-06 | 194 | 65 | 5 | 11c79a8c56ece42713b04b321982e41e239f07a5 | |
| ToppCell | RV-02._Fibroblast_II|World / Chamber and Cluster_Paper | 9.72e-06 | 195 | 65 | 5 | ce90b30dcdb56d4cd925cdb79fd9d7cefd998f48 | |
| ToppCell | Monocytes-NUPR1+_Monocytes|Monocytes / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues | 1.02e-05 | 197 | 65 | 5 | 8a058c9d9285acd7cf2fb8e34f7602a86b5d6c89 | |
| ToppCell | 10x5'v1-week_12-13-Myeloid_macrophage-stroma-stromal_macrophage|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 1.02e-05 | 197 | 65 | 5 | 075044c17f1c52008cd3c292c15cbf485b50411e | |
| ToppCell | COPD-Myeloid-Macrophage|Myeloid / Disease state, Lineage and Cell class | 1.07e-05 | 199 | 65 | 5 | 1cf1b2d6debf9e3389f1829dcaa2857e9533a080 | |
| ToppCell | E16.5-samps-Myeloid-Fetal_macrophage-macrophage_-_intermediate_-_unactivated|E16.5-samps / Age Group, Lineage, Cell class and subclass | 6.86e-05 | 150 | 65 | 4 | 60fdd266aaca1b589b9a77465a4a7fad4921339a | |
| ToppCell | facs-Marrow-KLS-18m-Lymphocytic-NK_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.79e-05 | 155 | 65 | 4 | c58a5fb8d853f12204e961d633e83452eb12a659 | |
| ToppCell | facs-MAT-Fat-24m-Myeloid-macrophage|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.79e-05 | 155 | 65 | 4 | d0c1608f8f6b6f4174e51d610501c707cba5e015 | |
| ToppCell | facs-Marrow-KLS-18m-Lymphocytic-NK_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.79e-05 | 155 | 65 | 4 | 9cb8c42c2e451b2d4dcd7154a4b1bfd21bbb7ea8 | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Rspo4_Rxfp1_Chat|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 7.79e-05 | 155 | 65 | 4 | 3b8def9e8f66511736ea37f259511f7c8b7743af | |
| ToppCell | facs-Marrow-B-cells-3m-Lymphocytic-BM_CD8_+_CD4_T_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.81e-05 | 160 | 65 | 4 | 55f599df6e3b7a5a505df4b094c834281311d94a | |
| ToppCell | facs-Marrow-B-cells-3m-Lymphocytic-mature_alpha-beta_T_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.81e-05 | 160 | 65 | 4 | 296e53e1e0786346d38db2d4188b9a1c0430627b | |
| ToppCell | E18.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_G2M|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.24e-05 | 162 | 65 | 4 | ec29c6f1c31e41ddcb041a49c593910edaf0532c | |
| ToppCell | Sigmoid-Macrophage-Macrophage|Macrophage / Region, Cell class and subclass | 1.06e-04 | 168 | 65 | 4 | bb16e135b6ae0d66615420b61edd6f62f2a3233c | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.14e-04 | 171 | 65 | 4 | c3e3ea09c73050372314a89b282e36ba5f339d73 | |
| ToppCell | E16.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.16e-04 | 172 | 65 | 4 | 714172f31abd0d25261df6115ec6a9df491fa14b | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c01-FCGR3A|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.22e-04 | 174 | 65 | 4 | 9bb8159a62640756d18ecbade3bf32bcbb7dd590 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_ILC|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.22e-04 | 174 | 65 | 4 | e70cc623a3a6aceec813ed852fec0c4240561133 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_ILC-NK_cell|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.22e-04 | 174 | 65 | 4 | b6725086fe5a2b057c7c495ec63c970ac52c2580 | |
| ToppCell | droplet-Heart-HEART-1m-Hematologic|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.24e-04 | 175 | 65 | 4 | 43b9cfd7c47d57244565c641e57f3256b5900804 | |
| ToppCell | droplet-Heart-HEART-1m-Hematologic-leukocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.24e-04 | 175 | 65 | 4 | a2fed97cf8d28f9936fe791e5e8c43d2430330c9 | |
| ToppCell | COPD-Epithelial-Basal|Epithelial / Disease state, Lineage and Cell class | 1.33e-04 | 178 | 65 | 4 | 441d1dba720141891b11f404744c59834d80e6c5 | |
| ToppCell | 3'-Child04-06-SmallIntestine-Hematopoietic-Myeloid-pDC|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.36e-04 | 179 | 65 | 4 | bbd4f8e988ef3f343aaedbc992b70f2bb6aff5f6 | |
| ToppCell | PCW_13-14-Hematologic_Myeloid-Hem_Myeloid_dendritic-im_conventional_dendritic_(19)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 1.36e-04 | 179 | 65 | 4 | 9fc44637c9a7551fd47b8533e45a9c199e164a95 | |
| ToppCell | LA-01._Fibroblast_I|LA / Chamber and Cluster_Paper | 1.36e-04 | 179 | 65 | 4 | dcb6ec9ae72b13fe388b72dace2815293fafe8ee | |
| ToppCell | facs-Aorta-Heart-3m-Myeloid-macrophage|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.45e-04 | 182 | 65 | 4 | df26388c0c46d1c4775103c8e802937b4d4e7470 | |
| ToppCell | PND01-Immune-Immune_Myeloid-Monocytic-Macrophage-AM-AM_prolif|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.45e-04 | 182 | 65 | 4 | 57f8b8d7b132f3ad6f2b1e79c3812fe938657d2c | |
| ToppCell | Control-Epithelial-Basal|Epithelial / Disease state, Lineage and Cell class | 1.54e-04 | 185 | 65 | 4 | d5d6d13e2f20b54ca55645b9a757b8599f4fd897 | |
| ToppCell | PND03-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.60e-04 | 187 | 65 | 4 | 6ab51e17a7782c2ae6394cad813dc3a2cde70c89 | |
| ToppCell | droplet-Bladder-BLADDER-1m-Epithelial-bladder_urothelial_cell|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.60e-04 | 187 | 65 | 4 | aa336fb568a24e12c0454265ddd71ed10a6614cf | |
| ToppCell | lymphoid-NK_cell-TNFRSF18+IL7R+_NK_cell|lymphoid / Lineage, cell class and subclass | 1.60e-04 | 187 | 65 | 4 | 99dfa50f6325b0d66d23ee8dcaa6437e7161628a | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.64e-04 | 188 | 65 | 4 | d8decd9b5967873ca8320c2f9f07365f163c777f | |
| ToppCell | facs-Pancreas-Exocrine-3m-Epithelial-pancreatic_ductal_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.64e-04 | 188 | 65 | 4 | 842982de2197770f999a70083ed9fca40ac22d79 | |
| ToppCell | facs-Pancreas-Exocrine-3m-Epithelial-pancreatic_ductal_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.64e-04 | 188 | 65 | 4 | a0815eaf68eedd6e5ec4af520df80a6ab4eb0864 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.67e-04 | 189 | 65 | 4 | e9df7ecd36bee1fedce23bb188c68a94fa60462c | |
| ToppCell | RV-15._Ventricular_Cardiomyocyte_III|RV / Chamber and Cluster_Paper | 1.71e-04 | 190 | 65 | 4 | 93c3188dfeb0b2f9889f8ae9b9c1f2f34129c99b | |
| ToppCell | droplet-Thymus-nan-18m-Lymphocytic-immature_T_cell|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.71e-04 | 190 | 65 | 4 | a550806f015d26f809df51a9af04541f2d16a2fc | |
| ToppCell | Control-Myeloid-Transitioning_MDM|Control / group, cell type (main and fine annotations) | 1.71e-04 | 190 | 65 | 4 | d6fd8c23cde4a10cc1517b6899a5a855fdfff2e2 | |
| ToppCell | 3'-GW_trimst-2-SmallIntestine-Endothelial-lymphatic_endothelial-LEC4_(STAB2+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.71e-04 | 190 | 65 | 4 | b2bd2cb384bb8a5662064ed1aee68e905e1f780d | |
| ToppCell | LV-01._Fibroblast_I|World / Chamber and Cluster_Paper | 1.71e-04 | 190 | 65 | 4 | 12992ec80a7b4f4f17de693f0719ee061a9918fd | |
| ToppCell | Control-Myeloid-cDC2|World / Disease state, Lineage and Cell class | 1.74e-04 | 191 | 65 | 4 | 11dfd8f38beb294f42710cfbd355cb089e1023c0 | |
| ToppCell | E18.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.74e-04 | 191 | 65 | 4 | 08b1d3b3be78bf7fd9e9039027e35275f2be88d0 | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW19|fetalBrain_Zhong_nature / Sample Type, Dataset, Time_group, and Cell type. | 1.74e-04 | 191 | 65 | 4 | b5328733da3d3d77c4f6fc5e2ba2035f8898f172 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-D|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.74e-04 | 191 | 65 | 4 | cf217d00ba2b0402a8e72fcd64bdb36d5539dde0 | |
| ToppCell | E18.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.74e-04 | 191 | 65 | 4 | f896fb490c4a17adac5e00ed9b6e6145eab1e564 | |
| ToppCell | droplet-Thymus-nan-18m-Lymphocytic-DN_to_DP_transition_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination__)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.74e-04 | 191 | 65 | 4 | 4bd9db45e7b5c0d04368e08c8199d390744aa317 | |
| ToppCell | COPD-Myeloid-cDC2|COPD / Disease state, Lineage and Cell class | 1.74e-04 | 191 | 65 | 4 | 2af6e4a6bd1f2193ece2131c3b7d976dd23a6966 | |
| ToppCell | IPF-Myeloid-cDC2|World / Disease state, Lineage and Cell class | 1.74e-04 | 191 | 65 | 4 | 9fda87fb6bc5b8b6c0214ec909ebbc9f3f65319b | |
| ToppCell | COPD-Myeloid-cDC2|World / Disease state, Lineage and Cell class | 1.74e-04 | 191 | 65 | 4 | 4e4887175200a57e1b041f2f131e3df774df3509 | |
| ToppCell | COVID-19-lung-Macrophage_PPARGhi_CD5Lhi|lung / Disease (COVID-19 only), tissue and cell type | 1.74e-04 | 191 | 65 | 4 | dab953682b8c9ed680a799161f837f792a7e4f33 | |
| ToppCell | COPD-Myeloid-cDC2|Myeloid / Disease state, Lineage and Cell class | 1.78e-04 | 192 | 65 | 4 | 984cdc2f1d93e164bc946d63f58dacb629f82eb7 | |
| ToppCell | droplet-Thymus-nan-21m-Lymphocytic-DN_to_DP_transition_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination__)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.78e-04 | 192 | 65 | 4 | 7299a0bbba8998cff4c6fd136f7e2d644ee5bd45 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_perichondrial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.81e-04 | 193 | 65 | 4 | e5016959f24370579a8770787e96869f264cf7b3 | |
| ToppCell | Children_(3_yrs)-Immune-interstitial_macrophage_(C1Q_positive)-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.85e-04 | 194 | 65 | 4 | 663e7e7fe48157e808b4f1a0ea6ad41944e857a2 | |
| ToppCell | LA-02._Fibroblast_II|LA / Chamber and Cluster_Paper | 1.85e-04 | 194 | 65 | 4 | 234d1494c114cce77c619708bbcd8d5ce805f19b | |
| ToppCell | RA-08._Macrophage|RA / Chamber and Cluster_Paper | 1.85e-04 | 194 | 65 | 4 | ac26e5c71d5069622de72fa25a9c920887ac2c19 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c04-ANXA2|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.88e-04 | 195 | 65 | 4 | e06ff785c5542c86c335d956799e03f7ae8345a4 | |
| ToppCell | LA-08._Macrophage|LA / Chamber and Cluster_Paper | 1.88e-04 | 195 | 65 | 4 | 5e1d5bdb8874091f5a2b1d0a8cc9008165718a97 | |
| ToppCell | distal-Hematologic-EREG+_Dendritic-2|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.92e-04 | 196 | 65 | 4 | c17bb7b3992bfec194bfa310f201a5c64b35868e | |
| ToppCell | Adult-Immune-monocyte-D122|Adult / Lineage, Cell type, age group and donor | 1.92e-04 | 196 | 65 | 4 | 16b0acb6157534938ca83d4e909471e33a7d3c52 | |
| ToppCell | distal-Hematologic-EREG+_Dendritic|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.92e-04 | 196 | 65 | 4 | 14c6870d125fc2bdacf4199883399cec0dd3f569 | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Layer_VI_Pan-area|World / Primary Cells by Cluster | 1.96e-04 | 197 | 65 | 4 | 79b9e7f2e8e33b3c547f716be5667156c48b0dfc | |
| ToppCell | distal-2-Hematologic-EREG+_Dendritic|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.96e-04 | 197 | 65 | 4 | 6fcca7c071e35786b715adeb18be317d34315d7e | |
| ToppCell | Neuron-Postmitotic-Excitatory_Neuron_-Layer_VI_Pan-area-33|World / Primary Cells by Cluster | 1.96e-04 | 197 | 65 | 4 | d20f29088e9afd8a960d6f680075c380e550f8a7 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.96e-04 | 197 | 65 | 4 | 5c4cee914baf7cb43e9cb99cc9e3ae823856dc15 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 1.96e-04 | 197 | 65 | 4 | 0034bae02ee7fcfea520d453ca3c842ab6963b12 | |
| ToppCell | Parenchymal-NucSeq-Immune_Myeloid-Macrophage_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.00e-04 | 198 | 65 | 4 | e125eb8aa57c172e5518874da1bd25998292f5e2 | |
| ToppCell | Parenchymal-NucSeq-Immune_Myeloid-Macrophage_alveolar-Macro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.00e-04 | 198 | 65 | 4 | 0baeb8e2c199ff10bb5c829c523546af3c9227c1 | |
| ToppCell | Parenchymal-10x3prime_v2-Immune_Myeloid-Dendritic_cell-DC_2|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 2.00e-04 | 198 | 65 | 4 | 115f564af8d7b89ac0331d3831faaef694043fd4 | |
| ToppCell | Tracheal-NucSeq-Epithelial-Epi_airway_basal-Suprabasal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.00e-04 | 198 | 65 | 4 | 19d8ff3a4f911b13ecc34844202925475ad4d2ab | |
| ToppCell | Tracheal-NucSeq-Epithelial-Epi_airway_basal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.00e-04 | 198 | 65 | 4 | 5374b0e98d669f36a0571d3c006c7bd5e3c8e87f | |
| ToppCell | Tracheal-NucSeq-Epithelial-Epi_airway_basal-Basal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.04e-04 | 199 | 65 | 4 | 94a7867e800df352731796de8c24cba133c29622 | |
| ToppCell | Parenchymal-10x3prime_v2-Immune_Myeloid-Dendritic_cell|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 2.04e-04 | 199 | 65 | 4 | d330e28075096a09da3c27db8b52e364967c1e34 | |
| ToppCell | Parenchymal-10x3prime_v2-Immune_Myeloid-Macrophage_alveolar-Macro_alveolar|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 2.08e-04 | 200 | 65 | 4 | 6e50272d172b491200d9a255ed08e6d6998cfe02 | |
| ToppCell | Bronchial-NucSeq-Immune_Myeloid-Macrophage_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.08e-04 | 200 | 65 | 4 | a443e475e7a10c26a6173d1af961de6219e0e567 | |
| ToppCell | Parenchymal-10x3prime_v2-Immune_Myeloid-Macrophage_alveolar|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 2.08e-04 | 200 | 65 | 4 | 840be665639a53ba9bafc19f7a81ca1e0436e329 | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_airway_basal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.08e-04 | 200 | 65 | 4 | 8827653738a931e4a4545e0c7d75be12bed40740 | |
| ToppCell | mild-B_naive|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.08e-04 | 200 | 65 | 4 | 222789b897e2a683bbfd1d00b6fd8705015d90df | |
| ToppCell | Parenchymal-NucSeq-Immune_Myeloid-Macrophage_other-Macrophage_intermediate|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.08e-04 | 200 | 65 | 4 | 46f9c28b24e39acdf0481a02b6eb86ecdd83c504 | |
| ToppCell | Bronchial-NucSeq-Immune_Myeloid-Macrophage_alveolar-Macro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.08e-04 | 200 | 65 | 4 | ed785a6d08ca2b350dc3307b587eadfb2886d1f9 | |
| Computational | Neighborhood of CDKN1C | 5.40e-08 | 27 | 42 | 5 | GNF2_CDKN1C | |
| Computational | Neighborhood of EGFR | 1.33e-07 | 32 | 42 | 5 | GNF2_EGFR | |
| Computational | Neighborhood of IGFBP1 | 2.12e-07 | 35 | 42 | 5 | GNF2_IGFBP1 | |
| Computational | Neighborhood of MMP11 | 5.45e-07 | 42 | 42 | 5 | GNF2_MMP11 | |
| Computational | Neighborhood of TIMP2 | 8.68e-07 | 46 | 42 | 5 | GNF2_TIMP2 | |
| Computational | Neighborhood of KISS1 | 1.20e-06 | 49 | 42 | 5 | GNF2_KISS1 | |
| Drug | AC1L1IPV | 2.94e-11 | 43 | 64 | 7 | CID000004683 | |
| Drug | pP-8 | 2.51e-06 | 10 | 64 | 3 | CID000444681 | |
| Drug | Rgd Peptide | 4.80e-06 | 239 | 64 | 7 | CID000104802 | |
| Drug | Badg | 7.78e-06 | 2 | 64 | 2 | CID000125951 | |
| Drug | indomethacin, USP; Down 200; 20uM; MCF7; HG-U133A | 1.87e-05 | 196 | 64 | 6 | 262_DN | |
| Drug | Tetrahydroxy-1,4-quinone monohydrate [319-89-1]; Down 200; 21uM; MCF7; HT_HG-U133A | 1.92e-05 | 197 | 64 | 6 | 3338_DN | |
| Drug | Arecoline hydrobromide [300-08-3]; Up 200; 17uM; MCF7; HT_HG-U133A | 2.03e-05 | 199 | 64 | 6 | 5423_UP | |
| Drug | 4-allyloxyaniline | 2.33e-05 | 3 | 64 | 2 | CID006504204 | |
| Disease | cD177 antigen measurement | 3.43e-10 | 18 | 64 | 5 | EFO_0021866 | |
| Disease | Tinnitus | 1.86e-04 | 130 | 64 | 4 | HP_0000360 | |
| Disease | smoking status measurement, forced expiratory volume | 2.52e-04 | 11 | 64 | 2 | EFO_0004314, EFO_0006527 | |
| Disease | cortical thickness | 6.38e-04 | 1113 | 64 | 9 | EFO_0004840 | |
| Disease | visual perception measurement | 1.41e-03 | 223 | 64 | 4 | EFO_0009700 | |
| Disease | Weight Gain | 1.43e-03 | 102 | 64 | 3 | C0043094 | |
| Disease | response to angiotensin-converting enzyme inhibitor, response to angiotensin receptor blocker, angioedema | 1.46e-03 | 26 | 64 | 2 | EFO_0005325, EFO_0005532, EFO_0010735 | |
| Disease | Hypermetropia | 1.47e-03 | 103 | 64 | 3 | HP_0000540 | |
| Disease | cardiovascular age measurement | 1.81e-03 | 29 | 64 | 2 | EFO_0803380 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| FHYETKYVVLSYLGL | 11 | Q9BXK5 | |
| TAVYHEILIGYLEYV | 1411 | Q09472 | |
| YLEYVKKLGYTTGHI | 1421 | Q09472 | |
| EHEKYIEYYLVLDNG | 201 | Q9UKQ2 | |
| VVVIDSYYYGKLVIA | 266 | Q9H6U8 | |
| YKISTLYYQLGDHEL | 226 | Q13217 | |
| DLIKTYKHINEVYYA | 51 | Q9Y463 | |
| ILQHYYHYIFVTGVK | 366 | O15438 | |
| YYEVAGHLRTYKEVV | 1536 | Q8TEM1 | |
| EKIEDPVYGIYYVDH | 366 | Q96QZ7 | |
| YLLYYEILAKVDVSH | 236 | Q7Z3D4 | |
| YHELKHIVFVGSIEY | 871 | Q12791 | |
| ESYSIYVYKVLKRVH | 36 | Q6DN03 | |
| ESYSIYVYKVLKRVH | 36 | Q6DRA6 | |
| TVYVYGQEKYLLLHD | 461 | Q8IXI2 | |
| YLEEKEGLVDYYSHI | 306 | P21128 | |
| YTAYEEGVHLVEVLY | 1316 | Q14315 | |
| KAIYVEYGYHITKAS | 466 | Q96G03 | |
| IYRYVEGIVSLHYKT | 471 | P16050 | |
| DILYDIHYILIKATY | 1331 | P24043 | |
| VYYLSHLERITEEGY | 161 | P30679 | |
| GLYYDEYLKQVIDVL | 51 | P80303 | |
| IYVFLYHEKYKVVEL | 141 | Q15546 | |
| ASYHGLYYIITLVVV | 86 | Q16827 | |
| GKVAYTEADYYHTEL | 171 | P13674 | |
| KHVYYVRVLTGIYTH | 1736 | Q460N5 | |
| YPYIYHVLTKGEIKI | 621 | Q9NX05 | |
| YSDLGYYIINKLHHV | 106 | Q9HCJ1 | |
| GTEELYGYLKKYHID | 251 | P19784 | |
| VVYKLHYYHDGQAVR | 131 | Q6BAA4 | |
| YHYITSYVVDGQIII | 76 | Q9UQ72 | |
| YHYITSYVVDGEIII | 76 | P11464 | |
| TAGDIAHYYRDYVVK | 171 | Q9UJX0 | |
| DIYLLVGTYIKYQVA | 261 | Q5VU65 | |
| YHYITSYVVDGQIII | 76 | Q16557 | |
| GAILDYEIKYYEKEH | 471 | Q9UF33 | |
| YIEYIRVKGSNYHLS | 626 | Q96QE2 | |
| IDVKYIGVKSAYVSY | 121 | Q9NUM4 | |
| KLALYVYEYLLHVGA | 21 | P81877 | |
| ALYVYEYLLHVGAQK | 21 | Q9BWW4 | |
| EVLGYKVDYHVSLYI | 116 | Q07890 | |
| YHYITSYVVDGQIII | 76 | Q9UQ74 | |
| YHYIISYIVDGKIII | 76 | Q00887 | |
| IYEKVYHICVTVLIY | 191 | P25103 | |
| IVEHVDLGAYYYRKF | 481 | O43166 | |
| ETLYYVKVYLVLGDI | 1231 | Q8TE82 | |
| AILLSYLYYVFKVVH | 751 | Q75T13 | |
| VAPEHVKGYIYVEAY | 216 | O00267 | |
| VKGYIYVEAYKQTHV | 221 | O00267 | |
| YHYVTSYIVDGQIIK | 76 | Q13046 | |
| PDEKSIITYVVTYYH | 261 | Q01082 | |
| YVKTIAILGAGHYVY | 316 | Q8WTS1 | |
| DVVFLITKYGYIHLY | 271 | Q00610 | |
| ITKYGYIHLYDLETG | 276 | Q00610 | |
| ITKYGYLHLYDLESG | 276 | P53675 | |
| GTYALSLIYGKTVYH | 196 | P43403 | |
| LILHYDETYREVKYG | 86 | Q9H1C4 | |
| LVYKERVGEYSLYIG | 81 | P02743 | |
| YVLAVEAYHSVIKYY | 561 | Q8WVT3 | |
| LDYVEKYYHASLEPV | 121 | Q9UIV8 | |
| LYELKTYHEVVDEIY | 76 | Q5VTL8 | |
| ILFIYYVVHEEKKYI | 646 | Q7Z6L1 | |
| TIEYLTIIVYYYRKH | 46 | Q5MJ10 | |
| VYEAYRKGLIDHQTY | 4291 | Q15149 | |
| YLIEKGEYEAALTIY | 261 | Q5R3I4 | |
| EVLYHQILYASGKVY | 356 | Q01118 | |
| YHYITSYVVDGQIII | 76 | P11465 | |
| YLDAIYDVTVVYEGK | 221 | Q9NUQ2 |